You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3503 results
  1. Clinical-scale Production of Osteoprogenitor Cells

    SBC: Aastrom Biosciences, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Cells within the bone marrow are known to possess bone regenerative capacity, but they are limited in number. Increasing these osteoprogenitor cell populations through the use of ex vivo expansion technologies and combining these cells with a matri ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Clinical Human Cell Production System for Broad Use

    SBC: Aastrom Biosciences, Inc.            Topic: N/A

    The therapeutic potential of patient-specific cultured cells continues to rapidly grow for a range of medical needs, such as regenerative repair of damaged tissue, cancer, and infectious diseases. As a result, the motivation to commercialize patient-specific "cell products" is increasing rapidly as well. A large unmet need exists for the development of reliable clinical and commercial ceil manufac ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Cannula System for "Bridge to Recovery" Cardiac Assist

    SBC: ABIOMED, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cardiac failure is the, largest single cause of mortality in the United States today. With an increase in the use of long-term cardiac assist devices, there is also a need for the short-term "bridge to recovery" application. This application is intended to provide a low-cost temporary support for patients whose heart is capable of recovering. This "patient scr ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Error Reduction in Dipole-Source Localization Models

    SBC: ABRATECH CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): We are developing means to reduce errors in Dipole Source Localization (DSL). DSL is commonly used to analyze brain waves for clinical and research purposes. It is known from our work and the work of others that the models used to compute the DSL are not perfect, but it is not known how much the imperfect models affect the solutions obtained. Based upon our ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  5. FAS/FAE Multimedia Tools for Care Providers

    SBC: ACADEMIC EDGE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Prenatal exposure to alcohol is the leading causing of birth defects in the United States. Recent studies show prevalence rates in the US may be as high as 1% of live births (Burd L, Cotsonas-Hassler, et al., 2003). This means that each year, as many as 39,000 babies are born with FAS. Many more are born with fetal alcohol effects (FAE). Early diagnosis and app ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Digoxin Chiral Isolates as Improved Pharmaceuticals

    SBC: ACADEMIC PHARMACEUTICALS            Topic: N/A

    DESCRIPTION (provided by applicant): Digoxin is the first line pharmacologic therapy for CHF and AF. Digoxin increases cardiac contractility and blocks conduction through the AV node slowing the ventricular response to AF and thus slowing the rate of the beating ventricles permitting more time for the heart to fill. The recent Dig trial supports the use of digoxin in the treatment of CHF and the r ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Development of NET-Selective Piperidine-Based PET Ligand

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increasing global health burden resulting from serious brain disorders, particularly mood-related disorders such as depression. The economic burden of depression alone is immense. Of the $83.1 billion spent in 2000 on the treatment of depression and related expenses, $26.1 billion (31 percent) were direct medical cos ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Capsid assembly inhibitors for the treatment of AIDS

    SBC: Achillion Pharmaceuticals, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Current HIV-1 therapy suffers from inadequate viral load suppression due to poor compliance, resistance, and interactions with other drugs and can lead to spread of drug-resistant strains. The current drug cocktails need to include inhibitors of viral components that are likely to slow resistance development. One such target is the HIV-1 capsid, an essential vi ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Molecular Evolution of Chondroitinase ABCI for SCI

    SBC: Acorda Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Spinal cord injury (SCI) is a devastating event affecting approximately 11,000 individuals each year in the US alone. Although most victims survive, the individual is often paralyzed for the rest of his or her life. Sixty percent of injuries occur in individuals between the ages of 16 and 30. Life-time medical costs average about $1.5 million dollars per patie ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Effects of Chondroitinase and Training in Acute SCI

    SBC: Acorda Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Spinal cord injury (SCI) inflicts trauma to the cells and tissues of the central nervous system and typically results in debilitating loss of function below the level of injury, for which no effective treatment exists. Chondroitin Sulfate Proteoglycans (CSPGs) an important component of the glial scar. The majority are potently inhibitory for axonal growth and ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government